CDK2-IN-50 

CDK2-IN-50 is a CDK2 inhibitor (IC₅₀ = 0.77 nM). CDK2-IN-50 can induce G1 phase arrest, indicating that it has an effective CDK2/cyclin E targeting mechanism. CDK2-IN-50 also has a significant pro-apoptotic effect. CDK2-IN-50 can be used for the study of breast cancer^[1].

CDK2-IN-50 (Compound 8b) (10 μM) exhibits significant growth-inhibiting activity, with an average GI% of 90.51%^[1].
CDK2-IN-50 (0.01-100 μM) has a GI₅₀ value as low as 0.33 μM (for breast cancer cell lines), with an average GI₅₀ of 5.58 μM across the entire plate^[1].
CDK2-IN-50 (0.33 μM, 24 h) causes cell cycle arrest in the G1 phase, with 77.92% of cells in the G1 phase in MDA-MB-468 cells^[1].
CDK2-IN-50 (0.33 μM) induces early apoptosis in MDA-MB-468 cells at a rate of 15.21%, late apoptosis at a rate of 5.87%, and a total apoptosis rate of 21.08%^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

457.59

C₂₇H₂₇N₃O₂S

O=C(NC1=CC=C(C)C=C1)C2=C(N)C3=C(S2)N=C4CCCCCC4=C3C5=CC=C(OC)C=C5

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Ibrahim OF, et al. CDK2 inhibitors: rationally directed discovery of a novel potent lead derived from cyclohepta[e]thieno[2,3-b]pyridine. RSC Med Chem. 2025 Jul 24.  [Content Brief]